Language:

Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study

Circulation (New York, N.Y.), 2013-03, Vol.127 (10), p.1128-1138 [Peer Reviewed Journal]

2014 INIST-CNRS ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.112.000765 ;PMID: 23403476 ;CODEN: CIRCAZ

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study
Author: HOEPER, Marius M ; BARST, Robyn J ; MORRELL, Nicholas W ; PEACOCK, Andrew J ; SATOH, Toru ; SIMONNEAU, Gerald ; TAPSON, Victor F ; TORRES, Fernando ; LAWRENCE, David ; QUINN, Deborah A ; GHOFRANI, Hossein-Ardeschir ; BOURGE, Robert C ; FELDMAN, Jeremy ; FROST, Adaani E ; GALIE, Nazzareno ; ANGEL GOMEZ-SANCHEZ, Miguel ; GRIMMINGER, Friedrich ; GRÜNIG, Ekkehard ; HASSOUN, Paul M
Subjects: Adolescent ; Adult ; Aged ; Arterial hypertension. Arterial hypotension ; Benzamides ; Biological and medical sciences ; Blood and lymphatic vessels ; Cardiology. Vascular system ; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous ; Double-Blind Method ; Exercise Tolerance - drug effects ; Exercise Tolerance - physiology ; Familial Primary Pulmonary Hypertension ; Female ; Hematoma, Subdural - chemically induced ; Hematoma, Subdural - enzymology ; Hematoma, Subdural - physiopathology ; Humans ; Hypertension, Pulmonary - drug therapy ; Hypertension, Pulmonary - enzymology ; Hypertension, Pulmonary - physiopathology ; Imatinib Mesylate ; Male ; Medical sciences ; Middle Aged ; Piperazines - administration & dosage ; Piperazines - adverse effects ; Pneumology ; Protein Kinase Inhibitors - administration & dosage ; Protein Kinase Inhibitors - adverse effects ; Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases ; Pyrimidines - administration & dosage ; Pyrimidines - adverse effects ; Young Adult
Is Part Of: Circulation (New York, N.Y.), 2013-03, Vol.127 (10), p.1128-1138
Description: By its inhibitory effect on platelet-derived growth factor signaling, imatinib could be efficacious in treating patients with pulmonary arterial hypertension (PAH). Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES), a randomized, double-blind, placebo-controlled 24-week trial, evaluated imatinib in patients with pulmonary vascular resistance ≥ 800 dyne·s·cm(-5) symptomatic on ≥ 2 PAH therapies. The primary outcome was change in 6-minute walk distance. Secondary outcomes included changes in hemodynamics, functional class, serum levels of N-terminal brain natriuretic peptide, and time to clinical worsening. After completion of the core study, patients could enter an open-label long-term extension study. Of 202 patients enrolled, 41% patients received 3 PAH therapies, with the remainder on 2 therapies. After 24 weeks, the mean placebo-corrected treatment effect on 6-minute walk distance was 32 m (95% confidence interval, 12-52; P=0.002), an effect maintained in the extension study in patients remaining on imatinib. Pulmonary vascular resistance decreased by 379 dyne·s·cm(-5) (95% confidence interval, -502 to - 255; P<0.001, between-group difference). Functional class, time to clinical worsening, and mortality did not differ between treatments. Serious adverse events and discontinuations were more frequent with imatinib than placebo (44% versus 30% and 33% versus 18%, respectively). Subdural hematoma occurred in 8 patients (2 in the core study, 6 in the extension) receiving imatinib and anticoagulation. Imatinib improved exercise capacity and hemodynamics in patients with advanced PAH, but serious adverse events and study drug discontinuations were common. Further studies are needed to investigate the long-term safety and efficacy of imatinib in patients with PAH. URL: http://www.clinicaltrials.gov. Unique identifier: NCT00902174 (core study); NCT01392495 (extension).
Publisher: Hagerstown, MD: Lippincott Williams & Wilkins
Language: English
Identifier: ISSN: 0009-7322
EISSN: 1524-4539
DOI: 10.1161/CIRCULATIONAHA.112.000765
PMID: 23403476
CODEN: CIRCAZ
Source: GFMER Free Medical Journals
MEDLINE

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study

2014 INIST-CNRS ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.112.000765 ;PMID: 23403476 ;CODEN: CIRCAZ

Searching Remote Databases, Please Wait